N/A N=29 Efficacy of Cantharidin in Molluscum Contagiosum
Molluscum Contagiosum, Skin Disease
Primary: Patients Experiencing Complete Clearance of All Molluscum Lesions. — 1; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=256 A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
Molluscum Contagiosum
Primary: Proportion of Subjects Achieving Complete Clearance at Week 12 — 5; 16; 13; 18 Participants
Phase 3 N=266 Cantharidin Application in Molluscum Patients-1
Molluscum Contagiosum
Primary: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) — 74; 19 Participants — p=<0.0001
Phase 2 N=94 Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
Molluscum Contagiosum
Primary: Number of Subjects Who Achieve Complete Clearance at 6 Weeks — 10; 7; 2; 3 Participants
Phase 3 N=262 Cantharidin Application in Molluscum Patients
Molluscum Contagiosum
Primary: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) — 81; 15 Participants
Phase 3 N=891 A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
Molluscum Contagiosum
Primary: Complete Clearance of All Treatable MC at Week 12 — 144; 88 Participants
Phase 2 N=30 Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
Molluscum Contagiosum
Primary: Number of Participants With Total Lesion Clearance — 11 Participants
Phase 2 N=33 Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
Molluscum Contagiosum
Primary: The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following…
Phase 4 N=17 Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
Verruca Vulgaris · Molluscum Contagiosum Skin Infection
Primary: Numbers of Lesions With no Response — 8; 9 lesions — p=0.534
Phase 2 N=56 Cantharidin and Occlusion in Verruca Epithelium
Common Wart · Warts Hand · Warts
Primary: Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) — 4 Participants
N/A N=124 CellFX System for the Treatment of Cutaneous Non-Genital Warts
Warts · Warts Hand · Verruca
Primary: Percentage of Verrucae Cleared — 67.6 percentage of verrucae clearance